The GLP is committed to full transparency. Download and review our just-released 2019 Annual Report.

Second RNAi-based drug gains FDA approval, targeting rare genetic condition causing severe abdominal pain

| | November 27, 2019

The FDA has approved the second-ever drug based on a Nobel prize-winning technique known as RNA interference, Alnylam’s givosiran.

The medicine is intended to treat a rare genetic condition called acute hepatic porphyria that can cause attacks of severe abdominal pain. The drug, which will be branded as Givlaari, will cost $575,000 per year, the company announced [November 20]; after discounts, it expects the average price to be $442,000 per year. Each vial of the drug will cost $39,000.

RNA interference, or RNAi, lets scientists mute genes that aren’t functioning properly. Although scientists pioneered the technique decades ago, the FDA only approved the first RNAi-based drug, another of Alnylam’s, last year.

Related article:  African Americans and Latinos are underrepresented in Alzheimer’s research. Here are 4 ways to fix that

The drug’s approval is a good sign for other companies developing drugs based on the RNAi technique. The drug is the first to use a type of sugar called GalNAc that allows more precise delivery of drugs to liver cells — which could, potentially, reduce serious side effects associated with the drug going elsewhere in the body.

“This really is an important milestone for the whole field,” [Alnylam CEO John] Maraganore said.

Read full, original post: FDA approves Alnylam’s Givlaari, second-ever drug based on RNAi

The GLP aggregated and excerpted this article to reflect the diversity of news, opinion, and analysis. Click the link above to read the full, original article.
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend